Our Company
Our Company
Our Strategy
Governance
Governance
U.S. Leadership
U.S. Corporate Compliance
State Disclosure
Social Impact
Social Impact
Patient Advocacy
Diversity, Equity and Inclusion in and Beyond the Workplace
Responsible Business Values
Corporate Social Responsibility
Our Legacy
Our Science
Our Science
Our Pipeline
Clinical Trials and Results
Your Health
Your Health
Vaccines
Vaccines
Influenza
Respiratory Syncytial Virus
Medicines
Medicines
Immunology
Neurology
Oncology
Rare Blood Disorders
Rare Diseases
Cardiovascular Disease
Diabetes
Transplant
Products
Products
Prescription Products
Vaccine Products
Generics
Patient Support
Healthcare Professional Support
Partner With Us
Media
Investor Relations
Careers
Global
Home
Soliqua® 100/33 (insulin glargine and lixisenatide) injection 100 Units/mL and 33 mcg/mL
Other
Soliqua® 100/33 (insulin glargine and lixisenatide) injection 100 Units/mL and 33 mcg/mL